This site is intended only for healthcare professionals resident in the United Kingdom

Key data from the INO-VATE study video

Key data for Besponsa (inotuzumab ozogamicin) from the INO-VATE ALL study

Speaker: Dr. Anna Castleton

Duration: 05:22

Anna Castleton is a Consultant Haematologist at the Christie Hospital, Manchester, a position she has held since 2016. She is additionally the ALL Clinical Lead at the Christie Hospital and Regional Teenage and Young Adult Principal Treatment Centre. Anna has a special interest in ALL and adolescent and young adult haematology, and is the Principal Investigator for several clinical trials in these areas. She is a member of the National Cancer Research Institute Adult ALL Subgroup and the Childhood Leukaemia Clinicians Network. She has authored a number of peer-reviewed papers and presented at several national and international congresses.

In this video, Dr Castleton discusses the INO-VATE study with particular reference to the following:

Besponsa mechanism of action
Phase III INO-VATE study¹: Besponsa vs. standard chemotherapy
- Study population and eligibility
- Study endpoints: Remission Rates and Overall Survival
- Adverse Event profile
- Management of hepatic toxicity and veno-occlusive disease and risk factors
- Bridging to transplantation
- Number of cycles required to achieve remission rates

Reference:

1. Kantarjian HM, et al. New Engl J Med. 2016;375:740-53.

PP-INO-GBR-0287. June 2020

Prescribing information

BESPONSA® (inotuzumab ozogamicin) 1 mg powder for concentrate for solution for infusion

Legal category: Prescription only medicine. Cost: £8,048 per vial.

Click here to access the BESPONSA Summary of Product Characteristics hosted on Datapharm’s ‘electronic Medicines Compendium’.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Cytarabine 20 mg/mL and 100 mg/mL solution for infusion or injection

Legal category: Prescription only medicine. Basic NHS price: Cytarabine 100 mg/mL, supplied as single vials containing 100 mg/mL cytarabine in 10 mL (1 g), £39.00 or 20 mL (2 g), £77.50. Cytarabine 20 mg/mL supplied as vials containing 20 mg/mL cytarabine in 5 mL (100 mg) in packs of 5, £20.48 or 25 mL (500 mg) as single vials, £19.50.
Click here to access the cytarabine 20 mg/mL and click here to access the cytarabine 100 mg/mL Summary of Product Characteristics hosted on Datapharm’s ‘electronic Medicines Compendium’.